• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story.

作者信息

Maron Barry J, Rowin Ethan J, Maron Martin S

机构信息

HCM Institute, Tufts Medical Center, Boston, Massachusetts.

HCM Institute, Tufts Medical Center, Boston, Massachusetts.

出版信息

Am J Cardiol. 2021 May 15;147:145-146. doi: 10.1016/j.amjcard.2021.01.034. Epub 2021 Feb 4.

DOI:10.1016/j.amjcard.2021.01.034
PMID:33549527
Abstract
摘要

相似文献

1
Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story.左心室肥厚的消退对肥厚型心肌病患者真的是件好事吗？：新兴的马伐卡坦故事。
Am J Cardiol. 2021 May 15;147:145-146. doi: 10.1016/j.amjcard.2021.01.034. Epub 2021 Feb 4.
2
Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective.探索梗阻性肥厚型心肌病的新旧疗法：马伐卡坦的前景
Circulation. 2021 Mar 23;143(12):1181-1183. doi: 10.1161/CIRCULATIONAHA.120.051330. Epub 2021 Mar 22.
3
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.马卡丹特对梗阻性肥厚型心肌病有症状患者超声心动图特征的影响。
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.
4
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.马卡丹特治疗非梗阻性肥厚型心肌病有症状患者的疗效评估。
J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064.
5
Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.EXPLORER-HCM 研究的设计和原理：评价马卡坦特治疗有症状梗阻性肥厚型心肌病成人患者的疗效。
Circ Heart Fail. 2020 Jun;13(6):e006853. doi: 10.1161/CIRCHEARTFAILURE.120.006853. Epub 2020 Jun 5.
6
Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.马卡丹特 - 肥厚型心肌病症状患者药物治疗的新的特异性选择。
Kardiol Pol. 2021;79(9):949-954. doi: 10.33963/KP.a2021.0064. Epub 2021 Jul 16.
7
The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM.EXPLORER-HCM研究开启梗阻性肥厚型心肌病药物治疗新篇章。
Cardiovasc Res. 2020 Nov 1;116(13):e175-e178. doi: 10.1093/cvr/cvaa282.
8
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）：一项随机、双盲、安慰剂对照、3 期临床试验的健康状况分析。
Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15.
9
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.马伐卡坦对梗阻性肥厚型心肌病的心脏结构有积极影响：EXPLORER-HCM心脏磁共振亚研究分析。
Circulation. 2021 Feb 9;143(6):606-608. doi: 10.1161/CIRCULATIONAHA.120.052359. Epub 2020 Nov 15.
10
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.Mavacamten 治疗梗阻性肥厚型心肌病的临床试验。
Ann Intern Med. 2019 Jun 4;170(11):741-748. doi: 10.7326/M18-3016. Epub 2019 Apr 30.

引用本文的文献

1
Risk Factors for Left Ventricular Hypertrophy in Patients with Diabetic Kidney Disease: A Multi-Center Study.糖尿病肾病患者左心室肥厚的危险因素：一项多中心研究。
Int J Gen Med. 2023 May 8;16:1705-1712. doi: 10.2147/IJGM.S412230. eCollection 2023.
2
Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.新型负性肌力药物在症状性梗阻性肥厚型心肌病既定手术心肌切除术时代的未来作用。
J Am Heart Assoc. 2022 May 3;11(9):e024566. doi: 10.1161/JAHA.121.024566.